The purpose of this protocol is to conduct a randomized comparison of the efficacy and
tolerance of miltefosine, LAMB, and pentavalent antimony for the treatment of mucosal
leishmaniasis. With such controlled pharmacodynamic data, and additional considerations of
administrative convenience (oral >>IV) and cost, we hope that it will be possible for policy
makers, treatment professionals, and patients to choose the most appropriate therapy for ML.
Phase:
Phase 3
Details
Lead Sponsor:
Fundacion Nacional de Dermatologia
Collaborators:
ABF Foundation for Medical Research Centro Nacional de Enfermedades Tropicales CENETROP Hospital Dermatologico de Jorochito
Treatments:
Amphotericin B Liposomal amphotericin B Miltefosine